Head-to-head evidence
Doravirine vs Rilpivirine
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV reverse transcriptase · full HIV pipeline
Doravirine · Pifeltro
Marketed by Merck & Co.
NCT02275780 · Phase 3 · completed
This was a randomized, double-blind, active-controlled Phase 3 trial with 769 enrolled adults (385 doravirine, 384 darunavir/ritonavir). The primary endpoint was virologic suppression (HIV-1 RNA <50 copies/mL) at Week 48, a hard clinical endpoint. The non-inferiority comparison was met: the difference was 3.9 percentage points (95% CI -1.6 to 9.4), with the lower bound above the prespecified -10% margin. The trial therefore provides strong evidence that doravirine is non-inferior to darunavir/ritonavir.
Next expected readout: November 2026 · NCT04892654 (registry estimate)
Rilpivirine · Edurant
Marketed by Johnson & Johnson and partners
NCT00540449 · Phase 3 · completed
This was a large (690-participant), randomized, quadruple-blinded, active-controlled (efavirenz) phase 3 trial with a hard clinical endpoint (confirmed viral load <50 copies/mL). The pre-specified non-inferiority margin was clearly met, with the confidence interval for the treatment difference falling entirely within the allowed -12% boundary, so rilpivirine was shown to be as effective as efavirenz on the primary measure despite a somewhat higher rate of virologic failure and resistance emergence as a secondary finding.
Next expected readout: October 2026 · NCT05660980 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Doravirine's landscape · Rilpivirine's landscape